Table 2. Open phase 2/3 studies for patients with MSS or MMR-p CRC.
Immune target | Agent | Phase | Line | NCT number |
---|---|---|---|---|
PD-1 | Tremelimumab + durvalumab | II | Refractory | NCT03007407 |
MEDI4736 + cediranib | II | Refractory | NCT02484404 | |
Nivolumab + TAS-102 | II | Refractory | NCT02860546 | |
PD-1/TLR | Pembrolizumab + Poly-ICLC | I/II | Refractory | NCT02834052 |
NCT, national clinical trial; PD-1, programmed cell death-1; TLR, toll-like receptor.